Highlights from ASCO-GI 2021 from EORTC Gastrointestinal tract cancer group
Author
Date
2021-09Permanent link
https://hdl.handle.net/11351/7683DOI
10.1038/s41416-021-01474-y
ISSN
1532-1827
WOS
000687550400002
PMID
34426663
Abstract
Last year the field of immunotherapy was finally introduced to GI oncology, with several changes in clinical practice such as advanced hepatocellular carcinoma or metastatic colorectal MSI-H. At the virtual ASCO-GI symposium 2021, several large trial results have been reported, some leading to a change of practice. Furthermore, during ASCO-GI 2021, results from early phase trials have been presented, some with potential important implications for future treatments. We provide here an overview of these important results and their integration into routine clinical practice.
Keywords
Biliary tract cancer; Colorectal cancer; Drug developmentBibliographic citation
Koessler T, Alsina M, Arnold D, Ben-Aharon I, Lutz MP, Obermannova R, et al. Highlights from ASCO-GI 2021 from EORTC Gastrointestinal tract cancer group. Br J Cancer. 2021 Sep;125:911–919.
Audience
Professionals
This item appears in following collections
- HVH - Articles científics [4476]
- VHIO - Articles científics [1250]
The following license files are associated with this item:




